We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$5.41M
Cap. Flow %
-0.08%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.81%
2 Financials 1.53%
3 Miscellaneous 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
76
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$12.1M 0.17%
+127,200
New +$11M
KPTI icon
77
Karyopharm Therapeutics
KPTI
$34.9M
$11.9M 0.17%
41,460
-29,600
-42% -$6.42M
MRSN
78
DELISTED
Mersana Therapeutics
MRSN
$11.9M 0.17%
82,933
+7,288
+10% +$533K
XFOR icon
79
X4 Pharmaceuticals
XFOR
$359M
$11.6M 0.17%
36,216
+5,000
+16% +$1.79M
XLV icon
80
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
$11.5M 0.16%
+113,200
New +$10.9M
NGNE icon
81
Neurogene
NGNE
$674M
$11.1M 0.16%
+45,000
New +$4.48M
XBI icon
82
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$10.5M 0.15%
+110,000
New +$9.51M
OBSV
83
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.95M 0.14%
2,605,531
– –
FOMX
84
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$8.59M 0.12%
2,577,982
-2,210,914
-46% -$7.03M
ISEE
85
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.58M 0.12%
+1,000,000
New +$3.57M
XENE icon
86
Xenon Pharmaceuticals
XENE
$5.45B
$8.32M 0.12%
634,812
– –
EPIX
87
DELISTED
ESSA Pharma
EPIX
$8.1M 0.12%
1,471,853
– –
CTIC
88
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.9M 0.11%
5,000,000
– –
ACET icon
89
Adicet Bio
ACET
$79.7M
$7.2M 0.1%
43,128
– –
VRNA
90
DELISTED
Verona Pharma
VRNA
$7.19M 0.1%
1,250,396
– –
RNAC icon
91
Cartesian Therapeutics
RNAC
$239M
$6.85M 0.1%
95,969
– –
PFNX
92
DELISTED
Pfenex Inc.
PFNX
$6.75M 0.1%
+614,868
New +$6.11M
APTO
93
DELISTED
Aptose Biosciences, Inc.
APTO
$6.52M 0.09%
+2,556
New +$3.33M
ZGNX
94
CALL
DELISTED
Zogenix, Inc.
ZGNX
$6.52M 0.09%
+125,000
New +$5.72M
IONS icon
95
Ionis Pharmaceuticals
IONS
$7.85B
$6.46M 0.09%
+106,900
New +$6.37M
HCAT icon
96
Health Catalyst
HCAT
$129M
$6.23M 0.09%
179,598
– –
NBRV
97
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$6.13M 0.09%
18,578
– –
ANAB icon
98
AnaptysBio
ANAB
$1.62B
$6.11M 0.09%
+375,800
New +$8.89M
MIST icon
99
Milestone Pharmaceuticals
MIST
$115M
$5.83M 0.08%
+364,206
New +$6.44M
XLRN
100
DELISTED
Acceleron Pharma
XLRN
$5.7M 0.08%
+107,500
New +$4.9M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.